193 related articles for article (PubMed ID: 35393148)
1. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
Hassan PM; Ali T; Saber E; Asghar A; Delaram D; Mostafa SV; Maryam S; Maryam K; Talieh S; Ali KM; Mohammad P; Fereidoon K; Anahita B; Yury VB; Dagmar GR; Vicente VB; Alireza B; Kazem B
Vaccine; 2022 May; 40(20):2856-2868. PubMed ID: 35393148
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov DY; Dolzhikova IV; Zubkova OV; Tukhvatullin AI; Shcheblyakov DV; Dzharullaeva AS; Grousova DM; Erokhova AS; Kovyrshina AV; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Lubenets NL; Egorova DA; Shmarov MM; Nikitenko NA; Morozova LF; Smolyarchuk EA; Kryukov EV; Babira VF; Borisevich SV; Naroditsky BS; Gintsburg AL
Lancet; 2020 Sep; 396(10255):887-897. PubMed ID: 32896291
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
Front Immunol; 2022; 13():836745. PubMed ID: 35693788
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum to "Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein" [Vaccine 40(20) (2022) 2856-2868].
Pouriayevali MH; Teimoori A; Esmaeili S; Abdoli A; Doroud D; Salehi-Vaziri M; Shahali M; Kadkhodazadeh M; Sabouni T; Ali Khosravi M; Panahi M; Khoshroo F; Bahmanjeh A; Valdes-Balbin Y; Garcia-Rivera D; Verez-Bencomo V; Biglari A; Baesi K
Vaccine; 2022 Nov; 40(48):7009. PubMed ID: 36374711
[No Abstract] [Full Text] [Related]
5. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
Dulin H; Barre RS; Xu D; Neal A; Vizcarra E; Chavez J; Ulu A; Yang M-S; Khan SR; Wuang K; Bhakta N; Chea C; Wilson EH; Martinez-Sobrido L; Hai R
J Virol; 2024 Feb; 98(2):e0157123. PubMed ID: 38206036
[TBL] [Abstract][Full Text] [Related]
6. Robust and protective immune responses induced by heterologous prime-boost vaccination with DNA-protein dimeric RBD vaccines for COVID-19.
An Y; Zhao G; Duan H; Zhang N; Duan M; Xu S; Liu X; Han Y; Zheng T; Li X; Hou J; Zhang Z; Bi Y; Zhao X; Xu K; Dai L; Wang B; Gao GF
J Med Virol; 2023 Jul; 95(7):e28948. PubMed ID: 37436839
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
Sunagar R; Prasad SD; Ella R; Vadrevu KM
Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
[TBL] [Abstract][Full Text] [Related]
9. Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models.
Nazarian S; Olad G; Abdolhamidi R; Motamedi MJ; Kazemi R; Kordbacheh E; Felagari A; Olad H; Ahmadi A; Bahiraee A; Farahani P; Haghighi L; Hassani F; Hajhassan V; Nadi M; Sheikhi A; Salimian J; Amani J
Mol Immunol; 2022 Sep; 149():107-118. PubMed ID: 35802999
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Eugenia-Toledo-Romaní M; Verdecia-Sánchez L; Rodríguez-González M; Rodríguez-Noda L; Valenzuela-Silva C; Paredes-Moreno B; Sánchez-Ramírez B; Pérez-Nicado R; González-Mugica R; Hernández-García T; Bergado-Baez G; Pi-Estopiñán F; Cruz-Sui O; Fraga-Quintero A; García-Montero M; Palenzuela-Díaz A; Baró-Román G; Mendoza-Hernández I; Fernandez-Castillo S; Climent-Ruiz Y; Santana-Mederos D; Ramírez Gonzalez U; García-Vega Y; Pérez-Massón B; Guang-Wu-Chen ; Boggiano-Ayo T; Ojito-Magaz E; Rivera DG; Valdés-Balbín Y; García-Rivera D; Vérez-Bencomo V; ; Gómez-Maceo Y; Reyes-Matienzo R; Manuel Coviella-Artime J; Morffi-Cinta I; Martínez-Pérez M; Castillo-Quintana I; Garcés-Hechavarría A; Valera-Fernández R; Martínez-Bedoya D; Garrido-Arteaga R; Cardoso-SanJorge F; Quintero Moreno L; Ontivero-Pino I; Teresa Pérez-Guevara M; Morales-García M; Noa-Romero E; Orosa-Vázquez I; Díaz-Hernández M; Rojas G; Tundidor Y; García-López E; Muñoz-Morejon Y; Galano-Frutos E; Rodríguez-Alvarez J; Arteaga A; Medina Nápoles M; Espi Ávila J; Fontanies Fernández M
Vaccine; 2022 Jul; 40(31):4220-4230. PubMed ID: 35691871
[TBL] [Abstract][Full Text] [Related]
11. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
[TBL] [Abstract][Full Text] [Related]
12. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein.
Ozharovskaia TA; Zubkova OV; Dolzhikova IV; Gromova AS; Grousova DM; Tukhvatulin AI; Popova O; Shcheblyakov DV; Scherbinin DN; Dzharullaeva AS; Erokhova AS; Shmarov MM; Loginova SY; Borisevich SV; Naroditsky BS; Logunov DY; Gintsburg AL
Acta Naturae; 2019; 11(1):38-47. PubMed ID: 31024747
[TBL] [Abstract][Full Text] [Related]
14. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
15. Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice.
Pflumm D; Seidel A; Klein F; Groß R; Krutzke L; Kochanek S; Kroschel J; Münch J; Stifter K; Schirmbeck R
Front Immunol; 2023; 14():1231274. PubMed ID: 37753087
[TBL] [Abstract][Full Text] [Related]
16. Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
Kalodimou G; Jany S; Freudenstein A; Schwarz JH; Limpinsel L; Rohde C; Kupke A; Becker S; Volz A; Tscherne A; Sutter G
Viruses; 2023 May; 15(5):. PubMed ID: 37243266
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Sathe N; Shaikh S; Bhavsar M; Parte L; Gadiparthi A; Kad S; Sensarma S; Nalband H; Sangapillai R; Sivashanmuganathan S; Pusalkar R; Anandan S; Masand G; Pratapreddy K; Harinarayana Rao S; Gokhale A; Vidyadhar Reddy GEC; Karanam G; Phatarphekar A; Rao P; Ramana V; Ramnath RL
Vaccine; 2024 Feb; 42(5):1051-1064. PubMed ID: 37816655
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Immune Responses against HIV-1 with Adenovector (Gag and Tat) Prime/Protein Boost Regimen and GM-CSF Injection.
Hosseini Rouzbahani N; Bayanolhagh S; Gholami M; Esmaeilzadeh A; Bayat Jozani Z; Mohraz M; Pourfathollah AA
Iran J Allergy Asthma Immunol; 2016 Oct; 15(5):403-412. PubMed ID: 27917627
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Pérez-Rodríguez S; de la Caridad Rodríguez-González M; Ochoa-Azze R; Climent-Ruiz Y; Alberto González-Delgado C; Paredes-Moreno B; Valenzuela-Silva C; Rodríguez-Noda L; Perez-Nicado R; González-Mugica R; Martínez-Pérez M; Sánchez-Ramírez B; Hernández-García T; Díaz-Machado A; Tamayo-Rodríguez M; Martín-Trujillo A; Rubino-Moreno J; Suárez-Batista A; Dubed-Echevarría M; Teresa Pérez-Guevara M; Amoroto-Roig M; Chappi-Estévez Y; Bergado-Báez G; Pi-Estopiñán F; Chen GW; Valdés-Balbín Y; García-Rivera D; Verez-Bencomo V
Vaccine; 2022 Mar; 40(13):2068-2075. PubMed ID: 35164986
[TBL] [Abstract][Full Text] [Related]
20. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
